Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

265 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer.
Stockhammer P, Grant M, Wurtz A, Foggetti G, Expósito F, Gu J, Zhao H, Choi J, Chung S, Li F, Walther Z, Dietz J, Duffield E, Gettinger S, Politi K, Goldberg SB. Stockhammer P, et al. Among authors: wurtz a. J Thorac Oncol. 2024 Feb;19(2):240-251. doi: 10.1016/j.jtho.2023.10.001. Epub 2023 Oct 6. J Thorac Oncol. 2024. PMID: 37806385 Free article.
Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer.
de Bruin EC, Cowell C, Warne PH, Jiang M, Saunders RE, Melnick MA, Gettinger S, Walther Z, Wurtz A, Heynen GJ, Heideman DA, Gómez-Román J, García-Castaño A, Gong Y, Ladanyi M, Varmus H, Bernards R, Smit EF, Politi K, Downward J. de Bruin EC, et al. Among authors: wurtz a. Cancer Discov. 2014 May;4(5):606-19. doi: 10.1158/2159-8290.CD-13-0741. Epub 2014 Feb 17. Cancer Discov. 2014. PMID: 24535670 Free PMC article.
Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.
Pirazzoli V, Nebhan C, Song X, Wurtz A, Walther Z, Cai G, Zhao Z, Jia P, de Stanchina E, Shapiro EM, Gale M, Yin R, Horn L, Carbone DP, Stephens PJ, Miller V, Gettinger S, Pao W, Politi K. Pirazzoli V, et al. Among authors: wurtz a. Cell Rep. 2014 May 22;7(4):999-1008. doi: 10.1016/j.celrep.2014.04.014. Epub 2014 May 9. Cell Rep. 2014. PMID: 24813888 Free PMC article.
Oncogenic EGFR Represses the TET1 DNA Demethylase to Induce Silencing of Tumor Suppressors in Cancer Cells.
Forloni M, Gupta R, Nagarajan A, Sun LS, Dong Y, Pirazzoli V, Toki M, Wurtz A, Melnick MA, Kobayashi S, Homer RJ, Rimm DL, Gettinger SJ, Politi K, Dogra SK, Wajapeyee N. Forloni M, et al. Among authors: wurtz a. Cell Rep. 2016 Jul 12;16(2):457-471. doi: 10.1016/j.celrep.2016.05.087. Epub 2016 Jun 23. Cell Rep. 2016. PMID: 27346347 Free PMC article.
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.
Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, Du VY, Schlessinger J, Goldberg SB, Chiang A, Sanmamed MF, Melero I, Agorreta J, Montuenga LM, Lifton R, Ferrone S, Kavathas P, Rimm DL, Kaech SM, Schalper K, Herbst RS, Politi K. Gettinger S, et al. Among authors: wurtz a. Cancer Discov. 2017 Dec;7(12):1420-1435. doi: 10.1158/2159-8290.CD-17-0593. Epub 2017 Oct 12. Cancer Discov. 2017. PMID: 29025772 Free PMC article.
Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non-Small Cell Lung Cancer.
Gettinger SN, Wurtz A, Goldberg SB, Rimm D, Schalper K, Kaech S, Kavathas P, Chiang A, Lilenbaum R, Zelterman D, Politi K, Herbst RS. Gettinger SN, et al. Among authors: wurtz a. J Thorac Oncol. 2018 Jun;13(6):831-839. doi: 10.1016/j.jtho.2018.03.008. Epub 2018 Mar 22. J Thorac Oncol. 2018. PMID: 29578107 Free PMC article.
EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.
Marcoux N, Gettinger SN, O'Kane G, Arbour KC, Neal JW, Husain H, Evans TL, Brahmer JR, Muzikansky A, Bonomi PD, Del Prete S, Wurtz A, Farago AF, Dias-Santagata D, Mino-Kenudson M, Reckamp KL, Yu HA, Wakelee HA, Shepherd FA, Piotrowska Z, Sequist LV. Marcoux N, et al. Among authors: wurtz a. J Clin Oncol. 2019 Feb 1;37(4):278-285. doi: 10.1200/JCO.18.01585. Epub 2018 Dec 14. J Clin Oncol. 2019. PMID: 30550363 Free PMC article.
EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer.
Hastings K, Yu HA, Wei W, Sanchez-Vega F, DeVeaux M, Choi J, Rizvi H, Lisberg A, Truini A, Lydon CA, Liu Z, Henick BS, Wurtz A, Cai G, Plodkowski AJ, Long NM, Halpenny DF, Killam J, Oliva I, Schultz N, Riely GJ, Arcila ME, Ladanyi M, Zelterman D, Herbst RS, Goldberg SB, Awad MM, Garon EB, Gettinger S, Hellmann MD, Politi K. Hastings K, et al. Among authors: wurtz a. Ann Oncol. 2019 Aug 1;30(8):1311-1320. doi: 10.1093/annonc/mdz141. Ann Oncol. 2019. PMID: 31086949 Free PMC article.
The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma.
Truini A, Starrett JH, Stewart T, Ashtekar K, Walther Z, Wurtz A, Lu D, Park JH, DeVeaux M, Song X, Gettinger S, Zelterman D, Lemmon MA, Goldberg SB, Politi K. Truini A, et al. Among authors: wurtz a. Clin Cancer Res. 2019 Nov 1;25(21):6382-6391. doi: 10.1158/1078-0432.CCR-19-0780. Epub 2019 Jun 10. Clin Cancer Res. 2019. PMID: 31182434 Free PMC article.
Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo.
Foggetti G, Li C, Cai H, Hellyer JA, Lin WY, Ayeni D, Hastings K, Choi J, Wurtz A, Andrejka L, Maghini DG, Rashleigh N, Levy S, Homer R, Gettinger SN, Diehn M, Wakelee HA, Petrov DA, Winslow MM, Politi K. Foggetti G, et al. Among authors: wurtz a. Cancer Discov. 2021 Jul;11(7):1736-1753. doi: 10.1158/2159-8290.CD-20-1385. Epub 2021 Mar 11. Cancer Discov. 2021. PMID: 33707235 Free PMC article.
265 results